6533b7dbfe1ef96bd1270c89
RESEARCH PRODUCT
Γδ T Cell-Based Immunotherapy in Melanoma: State of the Art
Toia F.Di Stefano A. B.Meraviglia S.Lo Presti E.Pirrello R.Rinaldi G.Fulfaro F.Dieli F.Cordova A.Pant A. B.subject
0301 basic medicinebusiness.industrymedicine.medical_treatmentMelanomaT cellCancerReview ArticleImmunotherapymedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogenslcsh:RC254-28203 medical and health sciences030104 developmental biology0302 clinical medicineImmune systemmedicine.anatomical_structureOncologyAntigen030220 oncology & carcinogenesismedicineCancer researchbusinessT-Lymphocytes | Receptors Antigen T-Cell gamma-delta | Cell subsetsAdjuvantEx vivodescription
Metastatic melanoma is still associated with a poor prognosis, and there is increasing interest in immunotherapy alone or in combination with other adjuvant therapies. Γδ T lymphocytes play a pivot role in the immune response against cancer, but while γδ-based immunotherapy is already a clinical reality for several solid tumors, data on melanoma are still limited and fragmented. This systematic review presents preclinical and clinical evidence for a role of γδ T lymphocytes in immunotherapeutic strategies for advanced melanoma and discusses research state of the art and future perspectives. Current strategies focus on in vivo stimulation, and ex vivo adoptive therapy and vaccination; results are promising, but further studies are needed to better investigate the interactions in tumoral microenvironment and to improve clinical efficacy of immunotherapeutic protocols.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2019-01-01 | Journal of Oncology |